Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-06 1:58 pm Purchase |
2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
FRANKLIN RESOURCES INC BEN |
6,108,277 6.800% |
4,352,414 (+247.88%) |
Filing History |
| 2024-01-25 1:48 pm Purchase |
2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
BlackRock Inc. BLK |
7,453,371 8.500% |
380,690 (+5.38%) |
Filing History |
| 2024-01-25 11:11 am Unchanged |
2023-12-29 | 13G | Revance Therapeutics, Inc. RVNC |
JPMORGAN CHASE & CO JPM |
4,754,771 5.400% |
0 (Unchanged) |
Filing History |
| 2024-01-25 11:10 am Sale |
2023-12-29 | 13G | Revance Therapeutics, Inc. RVNC |
JPMORGAN CHASE & CO JPM |
4,754,771 5.400% |
-228,178 (-4.58%) |
Filing History |
| 2023-10-24 4:05 pm Purchase |
2023-10-17 | 13D | Revance Therapeutics, Inc. RVNC |
Teoxane SA | 6,550,800 7.400% |
2,105,000 (+47.35%) |
Filing History |
| 2023-09-01 09:12 am Purchase |
2023-08-22 | 13D | Revance Therapeutics, Inc. RVNC |
Teoxane SA | 4,445,800 5.000% |
4,445,800 (New Position) |
Filing History |
| 2023-02-14 4:22 pm Purchase |
2022-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
Palo Alto Investors LP | 5,283,609 6.420% |
914,243 (+20.92%) |
Filing History |
| 2023-02-14 4:02 pm Purchase |
2022-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
Polar Capital Holdings Plc | 4,848,633 5.900% |
4,848,633 (New Position) |
Filing History |
| 2023-02-14 07:33 am Purchase |
2022-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
Antara Capital LP | 5,239,600 6.400% |
5,239,600 (New Position) |
Filing History |
| 2023-02-13 2:49 pm Purchase |
2023-02-14 | 13G | Revance Therapeutics, Inc. RVNC |
Capital World Investors | 9,480,156 11.500% |
1,016,247 (+12.01%) |
Filing History |
| 2023-02-09 2:10 pm Purchase |
2022-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
GIC Private Ltd | 5,492,965 6.680% |
1,316,885 (+31.53%) |
Filing History |
| 2023-02-09 11:30 am Purchase |
2022-12-30 | 13G | Revance Therapeutics, Inc. RVNC |
The Vanguard Group | 4,496,316 5.470% |
894,019 (+24.82%) |
Filing History |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
BlackRock Inc. BLK |
7,072,681 8.600% |
1,738,582 (+32.59%) |
Filing History |
| 2023-01-27 12:22 pm Sale |
2022-12-30 | 13G | Revance Therapeutics, Inc. RVNC |
JPMORGAN CHASE & CO JPM |
4,982,949 6.000% |
-1,811,274 (-26.66%) |
Filing History |
| 2022-12-09 1:58 pm Purchase |
2022-12-12 | 13G | Revance Therapeutics, Inc. RVNC |
Capital World Investors | 8,463,909 10.300% |
4,751,909 (+128.01%) |
Filing History |
| 2022-02-14 5:04 pm Purchase |
2021-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
Palo Alto Investors LP | 4,369,366 6.090% |
4,369,366 (New Position) |
Filing History |
| 2022-02-11 3:31 pm Purchase |
2022-02-14 | 13G | Revance Therapeutics, Inc. RVNC |
Capital World Investors | 3,712,000 5.200% |
3,712,000 (New Position) |
Filing History |
| 2022-02-10 08:32 am Purchase |
2021-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
The Vanguard Group | 3,602,297 5.020% |
3,602,297 (New Position) |
Filing History |
| 2022-02-08 5:07 pm Purchase |
2021-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
GIC Private Ltd | 4,176,080 5.820% |
345,129 (+9.01%) |
Filing History |
| 2022-02-04 09:29 am Sale |
2021-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
Wellington Management Group LLP | 1,104,531 1.540% |
-2,293,341 (-67.49%) |
Filing History |